Alectinib Monotherapy Approved by the European Commission for ALK-Positive NSCLC

Monday, 10 June 2024 | Lung Cancer

The European Commission has granted approval for the use of the tyrosine kinase inhibitor (TKI) alectinib as an adjuvant treatment for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who are at high risk of recurrence following tumor resection.

To continue, please login or sign up first